Sharps announces update of first shipments under $50M SoloGard agreement

Sharps Technology (STSS) announced an update on the execution of its first shipments under the previously announced $50M SoloGard sales agreement, alongside a series of advanced manufacturing upgrades. Sharps has initiated the second shipment of its first commercial order of SoloGard syringes under a multi-year supply agreement with a U.S.-based leader in IV flushing solutions. In preparation for increasing production through the second half of the year, SoloGard manufacturing will be supported by newly installed molding and automation systems – investments that enable Sharps to meet anticipated demand in the second half of 2025 under the sales agreement. Sharps is currently executing a $400,000 purchase order, announced June 4, 2025, as part of a broader five-year agreement to supply up to 500 million SoloGard syringes, marking the company’s transition into revenue-generating commercial operations. The contract includes customized 10mL SoloGard smart safety syringes – FDA- and WHO-approved devices that feature ultra-low waste design, standard luer lock compatibility, and re-use prevention technology.